PPD’s Post

Developing therapies and bringing them to market is a complex process, especially when working with multiple vendors. Sponsors need a streamlined solution that delivers speed, simplicity and scalability to clinical trials, drug development and manufacturing. Our integrated solutions combine the expertise and technology of a contract research organization (CRO) and contract development and manufacturing organization (CDMO) to ensure simplified and scalable pathways, from concept to market. Learn more about our solutions. » https://bit.ly/3XBmdc8 #drugdevelopment #biopharmaceuticals #clinicalresearch

🔬 **Application Note Alert!** Dive into our latest findings as we demonstrate how Scissor can revolutionize excipient screening. Uncover a deeper understanding of their impact on formulations tailored for subcutaneous delivery. 📖 Curious to know more? Read our application note and discover how the Scissor N3 system might just be the solution you've been seeking. 👉 https://lnkd.in/ebJcRnR3 Explore the realm of possibilities with Scissor N3 – redefining the landscape of subcutaneous drug delivery! 💡 #Biopharmaceuticals #InnovationInHealthcare #DrugDeliveryTechnology

🔬 𝗠𝗼𝗿𝗲 𝗧𝗿𝗮𝘀𝘁𝘂𝘇𝘂𝗺𝗮𝗯 𝗮𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝘀   We've expanded our in-stock portfolio to include an additional batch of the original Trastuzumab (from Herceptin®). Access up to 8 batches of the original drug and choose from 6 different biosimilars on demand, empowering your research with flexibility and efficiency.   For tailored solutions and early drug development, explore our website to discover a range of licensed molecules available in smaller units. Our inventory also includes historical batches of original drugs and biosimilar molecules, supporting your research and development projects. 🛒💡   #Trastuzumab #Herceptin #Biopharmaceuticals #DrugDevelopment #Evidentic #AntibodyResearch #RnD #DrugDevelopment #ClinicalGrade #DrugDiscovery #BetterHealth #mab

Engaging patients is key! By measuring what matters, collecting experience data, and involving patients in research, we ensure healthcare meets real needs. Co-designing research and creating accessible communication materials is the new clinical development frontier. Continue the conversation with AESARA to keep healthcare patient-centered and responsive to evolving needs. #ValueandAccess #HEOR #AESARA #MarketAccess #ISPOR2024 #ISPOR #PatientEngagement #Biopharma #Biopharmaceutical #PatientCenteredCare #RWE #RealWorldEvidence

The introduction of X-ray irradiation (XI) as an alternative to gamma for sterilizing single use systems is a significant change that has potential to disrupt #biopharmaceutical supply chains. This new #BioPhorum publication provides a robust, consistent and repeatable methodology to identify risks and manage the change, minimising potential risk to patient supply. We are proud to have facilitated this collaboration of leading experts across the industry and accelerate the development of this tool for the benefit of all. #connect #collaborate #accelerate #xrayirradiation https://lnkd.in/eu_t7zyu

The stakes are high and the journey is long – our checklist can help accelerate your #drugdevelopment timeline and increase the likelihood of market success. Download it here: https://lnkd.in/gADr8EN8 #Biopharmaceuticals #nonclinical #RegulatoryExperience

Our latest blog delves into the complexities of commercializing rare disease therapies, focusing on the intricate balance between accelerated approvals and confirmatory trials. We explore strategic approaches to handling regulatory challenges, managing complex data, and communicating value effectively. Discover key strategies like leveraging real-world evidence and forming strategic partnerships to navigate this demanding landscape successfully. Learn how these insights can drive success in rare disease drug commercialization. https://lnkd.in/dyhPUvU9 Sujith Eramangalath #RareDisease #Pharmaceuticals #AcceleratedApproval #HealthcareInnovation #DrugDevelopment